Rapport Therapeutics, Inc.
RAPP
$47.42
$0.060.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 20.00M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 20.00M | -- | -- | -- |
| Cost of Revenue | 51.41M | 32.72M | -- | -- | 22.68M |
| Gross Profit | -51.41M | -12.72M | -- | -- | -22.68M |
| SG&A Expenses | 9.39M | 11.50M | 8.25M | 7.71M | 6.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.81M | 44.22M | 38.51M | 29.99M | 29.50M |
| Operating Income | -60.81M | -24.22M | -38.51M | -29.99M | -29.50M |
| Income Before Tax | -56.62M | -19.86M | -33.76M | -26.93M | -26.73M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -56.62M | -19.86M | -33.76M | -26.93M | -26.73M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -56.62M | -19.86M | -33.76M | -26.93M | -26.73M |
| EBIT | -60.81M | -24.22M | -38.51M | -29.99M | -29.50M |
| EBITDA | -60.59M | -23.99M | -38.24M | -29.73M | -29.24M |
| EPS Basic | -1.19 | -0.42 | -0.72 | -0.71 | -0.75 |
| Normalized Basic EPS | -0.75 | -0.26 | -0.45 | -0.44 | -0.47 |
| EPS Diluted | -1.19 | -0.42 | -0.72 | -0.71 | -0.75 |
| Normalized Diluted EPS | -0.75 | -0.26 | -0.45 | -0.44 | -0.47 |
| Average Basic Shares Outstanding | 47.47M | 47.24M | 46.98M | 37.93M | 35.44M |
| Average Diluted Shares Outstanding | 47.47M | 47.24M | 46.98M | 37.93M | 35.44M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |